A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence
Claudio Festuccia1, Miriam Corrado2, Alessandra Rossetti1
1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio (Coppito), 67100 L'Aquila, Italy.
Abstract:
The Eph kinases are the largest receptor tyrosine kinases (RTKs) family in humans. PC3 human prostate adenocarcinoma cells are a well-established model for studying Eph-ephrin pharmacology as they naturally express a high level of EphA2, a promising target for new cancer therapies. A pharmacological approach with agonists did not show significant efficacy on tumor growth in prostate orthotopic murine models, but reduced distal metastasis formation. In order to improve the comprehension of the pharmacological targeting of Eph receptors in prostate cancer, in the present work, we investigated the efficacy of Eph antagonism both in vitro and in vivo, using UniPR1331, a small orally bioavailable Eph-ephrin interaction inhibitor. UniPR1331 was able to inhibit PC3 cells' growth in vitro in a dose-dependent manner, affecting the cell cycle and inducing apoptosis. Moreover, UniPR1331 promoted the PC3 epithelial phenotype, downregulating epithelial mesenchymal transition (EMT) markers. As a consequence, UniPR1331 reduced in vitro PC3 migration, invasion, and vasculomimicry capabilities. The antitumor activity of UniPR1331 was confirmed in vivo when administered alone or in combination with cytotoxic drugs in PC3-xenograft mice. Our results demonstrated that Eph antagonism is a promising strategy for inhibiting prostate cancer growth, especially in combination with cytotoxic drugs.
Insights
Eph antagonism using UniPR1331 effectively inhibits prostate cancer cell growth and metastasis in preclinical models. This strategy shows promise, particularly when combined with traditional cytotoxic drugs for enhanced therapeutic outcomes.
Area of Science:
- Molecular biology
- Oncology
- Pharmacology
Background:
- Eph kinases, the largest receptor tyrosine kinase (RTK) family, are implicated in cancer.
- EphA2 is a key target in prostate cancer, with agonists showing limited efficacy on tumor growth but reducing metastasis.
- Understanding Eph receptor antagonism is crucial for developing novel prostate cancer therapies.
Purpose of the Study:
- To investigate the efficacy of Eph antagonism via UniPR1331, a novel Eph-ephrin interaction inhibitor.
- To evaluate UniPR1331's effects on prostate cancer cell growth, phenotype, and metastatic potential in vitro and in vivo.
Main Methods:
- Utilized PC3 human prostate adenocarcinoma cells as a model system.
- Administered UniPR1331 in vitro to assess cell growth, cell cycle, apoptosis, and epithelial mesenchymal transition (EMT) markers.
- Evaluated UniPR1331's impact on cell migration, invasion, and vasculomimicry in vitro.
- Tested UniPR1331's antitumor activity in vivo using PC3-xenograft mice, both as a single agent and in combination with cytotoxic drugs.
Main Results:
- UniPR1331 inhibited PC3 cell growth dose-dependently, impacting cell cycle and inducing apoptosis.
- UniPR1331 promoted an epithelial phenotype by downregulating EMT markers, reducing migration, invasion, and vasculomimicry.
- In vivo studies confirmed UniPR1331's antitumor activity in PC3-xenograft mice.
Conclusions:
- Eph antagonism represents a promising therapeutic strategy for prostate cancer.
- UniPR1331 demonstrates significant potential in inhibiting prostate cancer progression.
- Combining Eph antagonism with cytotoxic drugs may enhance treatment efficacy for prostate cancer.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Related Concept Videos
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
02:38Mitogens and the Cell Cycle
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...